Biocompatible Boron-Containing Prodrugs of Belinostat for the Potential Treatment of Solid Tumors
- 11 January 2018
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 9 (2) , 149-154
Abstract
Despite promising therapeutic utilities for treatment of hematological malignancies, histone deacetylase inhibitor (HDACi) drugs have not proven as effective in the treatment of solid tumors. To expand the clinical indications of HDACi drugs, we developed novel boron-containing prodrugs of belinostat (2), one of which efficiently releases active 2 through a cascade of reactions in cell culture and demonstrates activities comparable to 2 against a panel of cancer cell lines. Importantly, prodrug 7 is more efficacious than belinostat in vivo, not only inhibiting the growth of tumor but also reducing tumor volumes in an MCF-7 xenograft tumor model owing to its superior biocompatibility, which suggests its clinical potential in the treatment of solid tumors.Keywords
Funding Information
- National Cancer Institute (1 R43 CA213462-01A1)
- National Institute on Minority Health and Health Disparities (2 G12 MD007595)
- Louisiana Cancer Research Consortium, Xavier University of Louisiana
This publication has 42 references indexed in Scilit:
- Innovative Strategies for Selective Inhibition of Histone DeacetylasesCell Chemical Biology, 2016
- Boronic prodrug of endoxifen as an effective hormone therapy for breast cancerBreast Cancer Research and Treatment, 2015
- Reactive Oxygen Species‐Responsive Protein Modification and Its Intracellular Delivery for Targeted Cancer TherapyAngewandte Chemie International Edition, 2014
- Design, synthesis and antifungal activities of novel pyrrole alkaloid analogsEuropean Journal of Medicinal Chemistry, 2011
- Carbamate Prodrug Concept for Hydroxamate HDAC InhibitorsChemMedChem, 2011
- Hydrogen Peroxide Activated Matrix Metalloproteinase Inhibitors: A Prodrug ApproachAngewandte Chemie International Edition, 2010
- Histone deacetylase inhibitors: Potential in cancer therapyJournal of Cellular Biochemistry, 2009
- The role of histone deacetylases (HDACs) in human cancerMolecular Oncology, 2007
- Stability studies of vorinostat and its two metabolites in human plasma, serum and urineJournal of Pharmaceutical and Biomedical Analysis, 2006
- Increased Nox1 and hydrogen peroxide in prostate cancerThe Prostate, 2004